Wegovy dose steps: the titration schedule explained clearly

The myth that you should reach 2.4mg as fast as possible

The biggest misconception about Wegovy's titration is that the early doses are a waiting game, something to get through before the real treatment begins. Clinically, that framing causes problems. The 0.25mg starting dose exists because semaglutide slows gastric emptying, and your gut needs time to adapt. Rush the schedule and the nausea, vomiting and reflux that are already common side effects become severe enough to stop treatment entirely. That outcome helps nobody.

Novo Nordisk's phase 3 STEP 1 trial, published in the New England Journal of Medicine, recorded an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. That result came from the full titration sequence, not from hitting 2.4mg in week four. The dose steps are doing real physiological work throughout.

If you are researching the full picture of what Wegovy treatment involves, the Wegovy overview page covers the mechanism, eligibility and what a private consultation looks like from the start.

What actually happens at each dose level

0.25mg is the four-week starter. Appetite suppression is modest at this level; the main task is giving your digestive system time to adjust. Most people notice mild nausea, sometimes some loose stools, occasionally fatigue. These effects are real but typically manageable and settle as the weeks pass.

0.5mg and 1.0mg are where many people first notice meaningful changes in hunger and portion size. The prescriber is looking for tolerability at each step before writing the next dose, this is why the step-up process requires a clinical conversation rather than an automatic renewal. If side effects are significant at a given level, the prescriber may extend the time spent there rather than move up on a fixed four-week clock.

1.7mg is the penultimate step. By this point most patients have adapted well; GI side effects have usually settled into a pattern. The jump to 2.4mg is the final one on the standard schedule. The NHS semaglutide medicines page sets out what to expect at each level in plain language and is worth reading alongside any prescriber guidance you receive.

One practical note on timing: if you know a dose increase is coming and you have a holiday or a week of important social commitments on the horizon, flag it with your prescriber. Moving a step up just before a packed schedule is rarely the smoothest approach. Most people find a quieter week, or even a Monday order to align with the working week, is the better moment to adjust.

The 7.2mg pathway: a newer step beyond 2.4mg

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, making a higher maintenance dose available for adults with a BMI of 30 or above. This does not mean the titration principle disappears, the prescriber still works through the lower doses first, and the 7.2mg dose is only reached after the full sequence under clinical supervision. The Wegovy doses guide explains the 7.2mg pathway in more detail, including what the trial evidence says about average weight reduction at the higher dose.

It is worth knowing that specific dose availability is always confirmed at consultation, and if you want to understand how each Wegovy dose fits into the overall schedule before you speak to a prescriber, that page walks through what each step involves. Details on how private treatment is structured, including what a transparent price covers, are on the Wegovy price comparison page.

What your prescriber is watching for at each step

A prescriber reviewing a Wegovy repeat is not just rubber-stamping the next pen. They are checking whether weight change is tracking as expected, whether side effects are controlled, whether there are any new health changes that affect the plan, and whether the current dose is appropriate before the next level is written. This is the point of structured step-up dosing rather than a standing prescription that auto-renews without review.

Under NICE's recommendation for semaglutide (TA875), if less than 5% weight loss has been achieved after six months on the maintenance dose, continuing treatment is reviewed. That threshold is a clinical guide, not a punishment, it exists because the evidence for continuing when the medicine is not working for a particular person is limited. Private prescribers apply the same clinical reasoning. Our prescribers follow this approach at every repeat, which is why every order at nume is reviewed individually rather than issued automatically. There are no subscriptions, no auto-renewals. If you have questions about how the schedule applies to your specific situation, start a free consultation and our prescribers will go through the steps with you directly.